Published in J Am Acad Dermatol on September 01, 1990
Exserohilum: an emerging human pathogen. Eur J Clin Microbiol Infect Dis (2006) 1.45
SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob Agents Chemother (2000) 1.13
High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother (1991) 1.12
Mycotic keratitis due to Curvularia senegalensis and in vitro antifungal susceptibilities of Curvularia spp. J Clin Microbiol (1999) 1.11
In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens. Antimicrob Agents Chemother (1999) 1.03
Reflections on the approach to treatment of a mycologic disaster. Antimicrob Agents Chemother (2013) 0.96
Phaeohyphomycosis caused by Alternaria infectoria in a renal transplant recipient. J Clin Microbiol (2001) 0.95
Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob Agents Chemother (2004) 0.95
Hospital-acquired phaeohyphomycosis due to Exserohilum rostratum in a child with leukemia. Can J Infect Dis Med Microbiol (2007) 0.88
Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob Agents Chemother (2005) 0.85
Subcutaneous phaeohyphomycosis caused by Exophiala salmonis. Ann Lab Med (2012) 0.82
Phaeohyphomycosis presenting as a solitary nodulocystic lesion in a renal transplant patient. Indian Dermatol Online J (2015) 0.82
Subcutaneous abscess due to Pyrenochaeta romeroi in a renal transplant recipient. Singapore Med J (2014) 0.77
Surgical management of subcutaneous Colletotrichum gloeosporioides. BMJ Case Rep (2015) 0.77
Phaeohyphomycotic dermatitis in a giant panda (Ailuropoda melanoleuca) caused by Cladosporium cladosporioides. Med Mycol Case Rep (2013) 0.76
Cutaneous alternariosis in a renal transplant patient successfully treated with posaconazole: Case report and literature review. Med Mycol Case Rep (2017) 0.75
A rare case of phaeohyphomycosis caused by Fonsecaea pedrosoi in a child with nephrotic syndrome. Indian J Nephrol (2016) 0.75
Cerebral phaeohyphomycosis: a rare cause of brain abscess. J Korean Neurosurg Soc (2014) 0.75
Application of DNA typing methods to epidemiology and taxonomy of Candida species. J Clin Microbiol (1987) 13.21
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med (1991) 12.09
Metachromatic agar-diffusion methods for detecting staphylococcal nuclease activity. Appl Microbiol (1971) 10.60
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Diagnosis of coliform infection in acutely dysuric women. N Engl J Med (1982) 8.75
Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol (1988) 8.67
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
A Candida albicans dispersed, repeated gene family and its epidemiologic applications. Proc Natl Acad Sci U S A (1988) 7.75
Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis (1972) 7.47
Association of hemolysin production, hemagglutination of human erythrocytes, and virulence for chicken embryos of extraintestinal Escherichia coli isolates. Infect Immun (1978) 7.28
Causes of the acute urethral syndrome in women. N Engl J Med (1980) 6.91
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis (1991) 6.43
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol (1995) 6.02
Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother (1978) 5.94
Direct allelic variation scanning of the yeast genome. Science (1998) 5.90
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Disseminated gonococcal infection. Ann Intern Med (1971) 5.66
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 4.75
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis (1983) 4.42
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol (1994) 4.27
Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection. Ann Intern Med (1982) 3.95
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Miconazole in coccidiodomycosis. II. Therapeutic and pharmacologic studies in man. Am J Med (1976) 3.91
Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother (1982) 3.90
Treatment of invasive aspergillosis with itraconazole. Am J Med (1989) 3.87
Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters. Am Rev Respir Dis (1978) 3.75
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75
Use of potato flakes agar in clinical mycology. J Clin Microbiol (1982) 3.73
Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med (1991) 3.69
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol (1994) 3.62
Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgrad Med J (1979) 3.55
Antifungal susceptibility testing. Current state of technology, limitations, and standardization. Infect Dis Clin North Am (1993) 3.55
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1994) 3.46
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42
Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. J Clin Microbiol (1986) 3.40
Nuclease production and lysostaphin susceptibility of Staphylococcus aureus and other catalase-positive cocci. Appl Microbiol (1971) 3.40
Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis (1997) 3.27
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Miconazole in coccidioidomycosis. I. Assays of activity in mice and in vitro. J Infect Dis (1975) 2.99
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
Variability of agar dilution-replicator method of yeast susceptibility testing. Antimicrob Agents Chemother (1979) 2.84
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82
Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol (1994) 2.81
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
Cell-mediated immunity in Cryptococcosis. Cell Immunol (1974) 2.68
Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol (1995) 2.66
Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med (1990) 2.66
Restriction endonuclease analysis of total cellular DNA of Aspergillus fumigatus isolates of geographically and epidemiologically diverse origin. J Infect Dis (1990) 2.66
Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol (1998) 2.65
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61
NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med (1994) 2.60
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
Mycoses caused by Candida lusitaniae. Rev Infect Dis (1988) 2.53
Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother (1990) 2.49
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol (1998) 2.48
Standardization of antifungal susceptibility testing. J Med Vet Mycol (1992) 2.43
Gentamicin therapy in renal failure: a nomogram for dosage. Ann Intern Med (1972) 2.43
Genetic characterization of pathogenic Saccharomyces cerevisiae isolates. Genetics (1994) 2.41
In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis (1992) 2.41
Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis (1982) 2.36
Analysis of Candida albicans phenotypes from different geographical and anatomical sources. J Clin Microbiol (1983) 2.33
Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester. J Infect Dis (1976) 2.31
Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol (1996) 2.28
In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother (1997) 2.27
Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med (1982) 2.25
The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis (2001) 2.25
Diagnostic usefulness and safety of transtracheal aspiration. N Engl J Med (1967) 2.23
Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother (1992) 2.22
Waterborne typhoid fever in Dade County, Florida. Clinical and therapeutic evaluation of 105 bacteremic patients. Am J Med (1975) 2.20
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol (2010) 2.19
Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol (2005) 2.18
Invasive aspergillosis. Rev Infect Dis (1984) 2.18
Emerging agents of phaeohyphomycosis: pathogenic species of Bipolaris and Exserohilum. J Clin Microbiol (1986) 2.17
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. J Clin Microbiol (1999) 2.15
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother (2000) 2.13
Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol (1995) 2.13
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12